NCT01893268已完成不适用
Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 279
- 试验地点
- 85
- 主要终点
- Proportion of patients treated with a chemotherapy in combination with Avastin including description of chemotherapy regimens and management of Avastin treatment
研究概览
简要总结
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >= 65 years of age
- •Diagnosis of advanced non squamous Non-Small Cell Lung Carcinoma (nsNSCLC, stage IIIB or IV) for whom the physician has decided to initiate a treatment with Avastin combined with chemotherapy as 1st line therapy
- •Having received oral and written information about the study, and having signed a written consent form
排除标准
- •Participation in a cancer clinical trial with an investigational medicinal product other than this study
- •Patient previously treated with Avastin
- •Patient under supervision or guardianship
结局指标
主要结局
Proportion of patients treated with a chemotherapy in combination with Avastin including description of chemotherapy regimens and management of Avastin treatment
时间窗: Approximately 4 years
次要结局
- Characteristics of patients with advanced non-squamous non-small cell lung cancer(Approximately 4 years)
- Tumor characteristics of patients with advanced non-squamous non-small cell lung cancer(Approximately 4 years)
- Progression-free survival(Approximately 4 years)
- Overall survival(Approximately 4 years)
- Quality of Life(Approximately 4 years)
- Safety: Incidence of adverse events(Approximately 4 years)
- Reasons of non-use of Avastin as first-line therapy(Approximately 4 years)
研究者
研究点 (85)
Loading locations...
相似试验
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01333007Hoffmann-La Roche423
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)Colorectal CancerNCT01697449Hoffmann-La Roche191
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)Colorectal CancerNCT01506167Hoffmann-La Roche719
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)Colorectal CancerNCT01674907Hoffmann-La Roche27
已完成
不适用
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)Ovarian CancerNCT01863693Hoffmann-La Roche300